• Home
  • Antibody-drug Conjugates Research
  • Antibody-drug Conjugates Manufacturing
  • News
Creative Biolabs ADC Blog

Menu

Skip to content
  • Home
  • Antibody-drug Conjugates Research
  • Antibody-drug Conjugates Manufacturing
  • News

Category Archives: Review

02Jul/23

The Future of ADC: Where to Go?

July 2, 2023ReviewADC drug, BCMA ADCbioadc

In 1913, the renowned German chemist Paul Ehrlich introduced the concept of the “magic bullet”, which is considered the earliest description of ADC drugs. In 2000, the FDA approved Mylotarg, the firstRead More…

02Jul/23

ADC Change: The Re-evolution of Treatment Patterns

July 2, 2023ReviewADC Therapybioadc

Reviewing the 100-year development history of tumor therapy, it has gone through three revolutions, and also led to the revolution of chemotherapy, targeted therapy. and immunotherapy. It can be said that changeRead More…

02Jul/23

The Origin of ADC

July 2, 2023ReviewADC drug, ADC Products, HER2 ADCbioadc

There are more than 650 active traditional ADC drugs currently, with only 14 having been approved to enter the market, and nearly 200 products still in different clinical research stages. Among them,Read More…

07Apr/23

ADC Combination Therapy: Combining with Immunotherapy

April 7, 2023Antibody-drug Conjugates Research, ReviewADC Combination Therapy, Immunotherapybioadc

Recently, combining immunotherapy with ADCs has entered clinical research, with growing evidence that ADCs may increase the efficacy of immunotherapy. Its mechanisms are varied, including inducing immunogenic cell death, dendritic cell maturation,Read More…

07Apr/23

ADC Combination Therapy: Combining with Targeted Drugs

April 7, 2023Antibody-drug Conjugates Research, ReviewADC Combination Therapy, Targeted Drugsbioadc

Compared to standard chemotherapy, ADC (antibody-drug conjugate) improves the therapeutic index, and its activity in patients with selective tumors makes it a potential partner for targeted drugs. Joint strategies can be conceivedRead More…

07Apr/23

ADC Combination Therapy: Combining with Chemotherapy

April 7, 2023Antibody-drug Conjugates Research, ReviewADC Combination Therapy, Chemotherapybioadc

Although ADC drugs have greatly improved the survival benefits of patients, the duration of their objective response or clinical benefits as a monotherapy is limited due to the emergence of drug resistanceRead More…

28Dec/22

ADC Panoramic Overview- Endocytosis of ADC Targeting Antigens

December 28, 2022ReviewADC Targeting Antigens, CD79b, HER2, Trop-2bioadc

CD33 CD33, a 67kda transmembrane glycoprotein receptor, is usually expressed in normal myeloid cells and it is the target of GO because it is preferentially overexpressed in AML cells. The intracellular immunoreceptorRead More…

28Dec/22

ADC Panoramic Overview- endocytosis pathway of ADC

December 28, 2022ReviewAdc Internalization, Endocytosisbioadc

Generally speaking, normal endocytosis can be divided into three stages: (1) bud formation; (2) membrane bending and vesicle maturation; and (3) membrane rupture and release into the cytoplasm. Multiple endocytosis pathways overlap,Read More…

07Dec/22

ADC Overview: Bioconjugation Technology Ⅲ

December 7, 2022ReviewADC, Bioconjugationbioadc

Bioconjugation with engineered unnatural amino acids In addition to the sulfur monoclonal antibody technique, the addition of non-standard amino acids (ncAA) provides another possibility for site-specific conjugation. This technique uses amino acidsRead More…

07Dec/22

ADC Overview: Bioconjugation TechnologyⅡ

December 7, 2022ReviewADC, Bioconjugation, payloadbioadc

Site-specific bioconjugation of engineered antibodies Advances in bioorthogonal chemistry and protein engineering have contributed to the production of more uniform ADC. Although there are many attachment methods available for natural McAbs, site-specificRead More…

Posts navigation

  • « Previous
  • 1
  • 2
  • 3
  • 4
  • 5
  • Next »

Categories

Recent Posts

  • Harnessing Synergy: How Antibody-Drug Conjugates and Immunotherapy Are Reshaping Breast Cancer Treatment
  • Fragment-Drug Conjugates: Innovations in ADC Development
  • Antibody-Oligonucleotide Conjugates (AOCs): Merging Precision and Therapeutic Potential
  • Bispecific ADCs: Redefining Precision in Targeted Cancer Therapy
  • The Future of Cancer Care: What Antibody-Drug Conjugates Will Bring and What We Have Already Done

Archives

Contact Us

USA - UK

Copyright © Creative Biolabs ADC Blog
Powered by WordPress , Theme i-max by TemplatesNext.
MENU
  • Home
  • Antibody-drug Conjugates Research
  • Antibody-drug Conjugates Manufacturing
  • News